What is NBIX's market cap?

$16.88B, based on the Nov 4 close of $166.05.

What is NBIX's P/E ratio?

24.0× trailing-twelve-month earnings of $702.50M.

Does Neurocrine Biosciences pay a dividend?

No regular cash dividend has been paid in the last year.

How much of NBIX is sold short?

6.4M shares, 6.6% of float, as of Oct 15, 2026.

What sector is NBIX in?

Healthcare, in the Biotechnology industry.

NASDAQ · NBIXHealthcareBiotechnology

Neurocrine Biosciences Inc (NBIX)

$166.05+0.73%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$166.05▲ 15.96% in range

Nov 4, 2025Low $123.10 · High $185.50Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Neurocrine Biosciences closed at $166.05 on Nov 4, up 0.73%, 10.5% below its 52-week closing high. Volume of 2.3M shares was 1.66× its 20-day average (above normal).

Split-adjusted performance: +14.1% over one month, +12.9% over six months, +17.0% over one year.

In the quarter ended Sep 30, 2026, revenue was $1.12B, up 41.2% from a year earlier, with a net margin of 18.4%.

Short interest was 6.4M shares at the Oct 15 settlement, up 10.2% from the prior report (6.6% of float, 4.5 days to cover).

Market cap$16.88B101.6M shares

Revenue · quarter$1.12B+41.2% YoY

Diluted EPS$1.96−3.9% YoY

P/E · TTM24.0×P/S 4.6×

Net margin18.4%Gross 97.6%

Dividend yieldNone

52-week range123.10 – 185.50−10.5% from high

Volume2.3M1.66× 20-day avg

Volatility · 60d36.5%Annualised

Short % of float6.6%4.5 days to cover

Net cash$737.9MCash $737.9M

Next earnings—Not scheduled

Split-adjusted performance

1W +14.1%1M +14.1%3M +3.9%6M +12.9%YTD +17.1%1Y +17.0%3Y +55.0%5Y +64.0%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum73

Revenue growth77

Net margin80

Value (low P/E)46

Size96

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →

Shares short6.4M+10.2% vs prior

Days to cover4.5Settled Oct 15

% of float6.6%

Short vol. 10d64.8%of daily volume

Closest peers by size in Biotechnology

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
NBIXNeurocrine Biosciences	$166.05	+0.73%	+12.9%	+41.2%	18.4%	24.0	$16.88B
EXELExelixis	$72.75	+0.61%	+49.4%	+10.2%	33.1%	20.1	$17.75B	Compare
HALOHalozyme Therapeutics	$130.34	+1.34%	+96.4%	+47.7%	47.8%	35.8	$14.79B	Compare
KYMRKymera Therapeutics	$136.25	+7.21%	+58.0%	−100.0%	—	—	$11.63B	Compare
TECHBio-Techne	$72.73	+0.10%	+53.4%	+1.3%	17.0%	62.8	$11.42B	Compare
RGENRepligen	$178.20	−0.04%	+41.7%	+10.9%	−18.4%	—	$11.31B	Compare
PCVXVaxcyte	$65.68	+8.01%	+15.0%	—	—	—	$10.34B	Compare
IBRXImmunityBio	$8.93	+7.72%	+6.6%	+93.9%	−449.6%	—	$9.46B	Compare
TWSTTwist Bioscience	$142.58	+1.63%	+139.5%	+23.2%	−29.6%	—	$9.45B	Compare

News about Neurocrine Biosciences

All news →

NBIX Beats on Q3 Earnings & Sales, Raises '26 Ingrezza Sales ViewZacks Investment Research · 1d ago▲ Positive Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top EstimatesZacks Investment Research · 2d agoNeutral Neurocrine (NBIX) Reports Q3 Earnings: What Key Metrics Have to SayZacks Investment Research · 2d ago▲ Positive Here's Why Neurocrine Biosciences (NBIX) is a Strong Growth StockZacks Investment Research · 5d ago▲ Positive Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?Zacks Investment Research · Oct 26, 2026Neutral

Quick answers

What does Neurocrine Biosciences do?: Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids.
What is NBIX's market cap?: $16.88B, based on the Nov 4 close of $166.05.
What is NBIX's P/E ratio?: 24.0× trailing-twelve-month earnings of $702.50M.
Does Neurocrine Biosciences pay a dividend?: No regular cash dividend has been paid in the last year.
How much of NBIX is sold short?: 6.4M shares, 6.6% of float, as of Oct 15, 2026.
What sector is NBIX in?: Healthcare, in the Biotechnology industry.

About Neurocrine Biosciences

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

HQ: San Diego, CA2,500 employeesListed May 23, 1996neurocrine.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology